These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 33521698)

  • 1. ATP-binding cassette transporters restrict drug delivery and efficacy against brain tumors even when blood-brain barrier integrity is lost.
    de Gooijer MC; Kemper EM; Buil LCM; Çitirikkaya CH; Buckle T; Beijnen JH; van Tellingen O
    Cell Rep Med; 2021 Jan; 2(1):100184. PubMed ID: 33521698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ABCG2 and ABCB1 Limit the Efficacy of Dasatinib in a PDGF-B-Driven Brainstem Glioma Model.
    Mittapalli RK; Chung AH; Parrish KE; Crabtree D; Halvorson KG; Hu G; Elmquist WF; Becher OJ
    Mol Cancer Ther; 2016 May; 15(5):819-29. PubMed ID: 26883271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efflux transporters at the blood-brain barrier limit delivery and efficacy of cyclin-dependent kinase 4/6 inhibitor palbociclib (PD-0332991) in an orthotopic brain tumor model.
    Parrish KE; Pokorny J; Mittapalli RK; Bakken K; Sarkaria JN; Elmquist WF
    J Pharmacol Exp Ther; 2015 Nov; 355(2):264-71. PubMed ID: 26354993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration.
    Tang SC; Lagas JS; Lankheet NA; Poller B; Hillebrand MJ; Rosing H; Beijnen JH; Schinkel AH
    Int J Cancer; 2012 Jan; 130(1):223-33. PubMed ID: 21351087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategies to Inhibit ABCB1- and ABCG2-Mediated Efflux Transport of Erlotinib at the Blood-Brain Barrier: A PET Study on Nonhuman Primates.
    Tournier N; Goutal S; Auvity S; Traxl A; Mairinger S; Wanek T; Helal OB; Buvat I; Soussan M; Caillé F; Langer O
    J Nucl Med; 2017 Jan; 58(1):117-122. PubMed ID: 27493269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioluminescent imaging of drug efflux at the blood-brain barrier mediated by the transporter ABCG2.
    Bakhsheshian J; Wei BR; Chang KE; Shukla S; Ambudkar SV; Simpson RM; Gottesman MM; Hall MD
    Proc Natl Acad Sci U S A; 2013 Dec; 110(51):20801-6. PubMed ID: 24297888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of ABCB1 and ABCG2 at the Mouse Blood-Brain Barrier with Marketed Drugs To Improve Brain Delivery of the Model ABCB1/ABCG2 Substrate [
    Traxl A; Mairinger S; Filip T; Sauberer M; Stanek J; Poschner S; Jäger W; Zoufal V; Novarino G; Tournier N; Bauer M; Wanek T; Langer O
    Mol Pharm; 2019 Mar; 16(3):1282-1293. PubMed ID: 30694684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of amyloid beta on ATP-binding cassette transporter expression and activity in porcine brain microvascular endothelial cells.
    Shubbar MH; Penny JI
    Biochim Biophys Acta Gen Subj; 2018 Oct; 1862(10):2314-2322. PubMed ID: 30048740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sildenafil is not a useful modulator of ABCB1 and ABCG2 mediated drug resistance in vivo.
    Lin F; Hoogendijk L; Buil L; Beijnen JH; van Tellingen O
    Eur J Cancer; 2013 May; 49(8):2059-64. PubMed ID: 23422148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux.
    Agarwal S; Sane R; Gallardo JL; Ohlfest JR; Elmquist WF
    J Pharmacol Exp Ther; 2010 Jul; 334(1):147-55. PubMed ID: 20421331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PET-CT imaging with [(18)F]-gefitinib to measure Abcb1a/1b (P-gp) and Abcg2 (Bcrp1) mediated drug-drug interactions at the murine blood-brain barrier.
    Vlaming ML; Läppchen T; Jansen HT; Kivits S; van Driel A; van de Steeg E; van der Hoorn JW; Sio CF; Steinbach OC; DeGroot J
    Nucl Med Biol; 2015 Nov; 42(11):833-41. PubMed ID: 26264927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier.
    Cisternino S; Mercier C; Bourasset F; Roux F; Scherrmann JM
    Cancer Res; 2004 May; 64(9):3296-301. PubMed ID: 15126373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PI3K-mTOR Pathway Inhibition Exhibits Efficacy Against High-grade Glioma in Clinically Relevant Mouse Models.
    Lin F; de Gooijer MC; Hanekamp D; Chandrasekaran G; Buil LC; Thota N; Sparidans RW; Beijnen JH; Würdinger T; van Tellingen O
    Clin Cancer Res; 2017 Mar; 23(5):1286-1298. PubMed ID: 27553832
    [No Abstract]   [Full Text] [Related]  

  • 14. ATP-binding cassette transporter inhibitor potency and substrate drug affinity are critical determinants of successful drug delivery enhancement to the brain.
    Lentzas A; de Gooijer MC; Zuidema S; Meurs A; Çitirikkaya CH; Venekamp N; Beijnen JH; van Tellingen O
    Fluids Barriers CNS; 2024 Aug; 21(1):62. PubMed ID: 39103921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Proof-of-Concept Study to Inhibit ABCG2- and ABCB1-Mediated Efflux Transport at the Human Blood-Brain Barrier.
    Bauer M; Karch R; Wulkersdorfer B; Philippe C; Nics L; Klebermass EM; Weber M; Poschner S; Haslacher H; Jäger W; Tournier N; Wadsak W; Hacker M; Zeitlinger M; Langer O
    J Nucl Med; 2019 Apr; 60(4):486-491. PubMed ID: 30237210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in dipole membrane potential at the mouse blood-brain barrier enhance the transport of 99mTechnetium Sestamibi more than inhibiting Abcb1, Abcc1, or Abcg2.
    Cattelotte J; Tournier N; Rizzo-Padoin N; Schinkel AH; Scherrmann JM; Cisternino S
    J Neurochem; 2009 Feb; 108(3):767-75. PubMed ID: 19067785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physical blood-brain barrier disruption induced by focused ultrasound does not overcome the transporter-mediated efflux of erlotinib.
    Goutal S; Gerstenmayer M; Auvity S; Caillé F; Mériaux S; Buvat I; Larrat B; Tournier N
    J Control Release; 2018 Dec; 292():210-220. PubMed ID: 30415015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain Distribution of Dual ABCB1/ABCG2 Substrates Is Unaltered in a Beta-Amyloidosis Mouse Model.
    Wanek T; Zoufal V; Brackhan M; Krohn M; Mairinger S; Filip T; Sauberer M; Stanek J; Pekar T; Pahnke J; Langer O
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33153231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [(18)F]FDG is not transported by P-glycoprotein and breast cancer resistance protein at the rodent blood-brain barrier.
    Wanek T; Traxl A; Bankstahl JP; Bankstahl M; Sauberer M; Langer O; Kuntner C
    Nucl Med Biol; 2015 Jul; 42(7):585-9. PubMed ID: 25823393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the blood-brain barrier without restriction by ABCB1 and ABCG2.
    Lin F; Buil L; Sherris D; Beijnen JH; van Tellingen O
    Int J Cancer; 2013 Sep; 133(5):1222-33. PubMed ID: 23436212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.